Current Atherosclerosis Reports最新文献

"Improving Diet Quality of Children with Dyslipidemia Who also Exhibit Picky Eating Behaviors". "改善同时表现出挑食行为的血脂异常儿童的饮食质量"。

IF 5.7 2区医学

Current Atherosclerosis Reports Pub Date : 2024-12-01 Epub Date: 2024-09-26 DOI: 10.1007/s11883-024-01242-2

Janet Carter

引用次数: 0

Targeting Inflammatory Pathways in Atherosclerosis: Exploring New Opportunities for Treatment. 针对动脉粥样硬化的炎症通路：探索治疗新机遇。

IF 5.7 2区医学

Current Atherosclerosis Reports Pub Date : 2024-12-01 Epub Date: 2024-10-15 DOI: 10.1007/s11883-024-01241-3

Alessia d'Aiello, Simone Filomia, Mattia Brecciaroli, Tommaso Sanna, Daniela Pedicino, Giovanna Liuzzo

{"title":"Targeting Inflammatory Pathways in Atherosclerosis: Exploring New Opportunities for Treatment.","authors":"Alessia d'Aiello, Simone Filomia, Mattia Brecciaroli, Tommaso Sanna, Daniela Pedicino, Giovanna Liuzzo","doi":"10.1007/s11883-024-01241-3","DOIUrl":"10.1007/s11883-024-01241-3","url":null,"abstract":"Purpose of the review: This review discusses the molecular mechanisms involved in the immuno-pathogenesis of atherosclerosis, the pleiotropic anti-inflammatory effects of approved cardiovascular therapies and the available evidence on immunomodulatory therapies for atherosclerotic cardiovascular disease (ACVD). We highlight the importance of clinical and translational research in identifying molecular mechanisms and discovering new therapeutic targets.Recent findings: The CANTOS (Canakinumab Anti-Inflammatory Thrombosis Outcomes Study) trial was the first to demonstrate a reduction in cardiovascular (CV) risk with anti-inflammatory therapy, irrespective of serum lipid levels. ACVD is the leading cause of death worldwide. Although targeting principal risk factors significantly reduces CV risk, residual risk remains unaddressed. The immunological mechanisms underlying atherosclerosis represent attractive therapeutic targets. Several commonly used and non-primarily anti-inflammatory drugs (i.e. SGLT2i, and PCSK9i) exhibit pleiotropic properties. Otherwise, recent trials have investigated the blockade of primarily inflammatory compounds, trying to lower the residual risk via low-dose IL-2, PTPN22 and CD31 pathway modulation. In the era of precision medicine, modern approaches may explore new pharmacological targets, identify new markers of vascular inflammation, and evaluate therapeutic responses.","PeriodicalId":10875,"journal":{"name":"Current Atherosclerosis Reports","volume":" ","pages":"707-719"},"PeriodicalIF":5.7,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11530513/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142460017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Myopathy in Statin-Treated Children and Adolescents: A Practical Approach. 他汀类药物治疗的儿童和青少年的肌病：实用方法。

IF 5.7 2区医学

Current Atherosclerosis Reports Pub Date : 2024-12-01 Epub Date: 2024-09-24 DOI: 10.1007/s11883-024-01239-x

Rae-Ellen W Kavey

引用次数: 0

PCSK9 Monoclonal Antibodies Have Come a Long Way. PCSK9 单克隆抗体取得了长足进步。

IF 5.7 2区医学

Current Atherosclerosis Reports Pub Date : 2024-12-01 Epub Date: 2024-10-10 DOI: 10.1007/s11883-024-01243-1

Sandra Zendjebil, Philippe Gabriel Steg

引用次数: 0

Transitioning Adolescents and Young Adults with Lipid Disorders to Adult Health Care. 让患有血脂紊乱症的青少年和年轻人过渡到成人医疗保健。

IF 5.7 2区医学

Current Atherosclerosis Reports Pub Date : 2024-12-01 Epub Date: 2024-10-02 DOI: 10.1007/s11883-024-01244-0

Christopher Schmitt, Thomas M Yohannan

引用次数: 0

Pericoronary Fat Attenuation: Diagnosis and Clinical Implications. 冠状动脉周围脂肪衰减：诊断与临床意义。

IF 5.7 2区医学

Current Atherosclerosis Reports Pub Date : 2024-12-01 Epub Date: 2024-10-10 DOI: 10.1007/s11883-024-01245-z

Malek Nayfeh, Maria Alwan, Ahmed Sayed, Mouaz H Al-Mallah

{"title":"Pericoronary Fat Attenuation: Diagnosis and Clinical Implications.","authors":"Malek Nayfeh, Maria Alwan, Ahmed Sayed, Mouaz H Al-Mallah","doi":"10.1007/s11883-024-01245-z","DOIUrl":"10.1007/s11883-024-01245-z","url":null,"abstract":"Purpose of the review: The purpose of this review is to evaluate the current state of knowledge regarding the technical challenges associated with the Post-Acquisition Fat Attenuation Index (PFAI). By examining the limitations and gaps in the current methodologies, this review aims to provide a comprehensive understanding of how various factors impact the accuracy and reliability of PFAI measurements.Recent findings: PFAI correlates with plaque instability, as inflammation in coronary plaque alters surrounding adipose tissue composition, increasing its water content and reducing lipid content, which is detectable via cardiac CT as increased attenuation. Recent studies have demonstrated PFA's prognostic value, with elevated levels linked to higher risks of cardiac events and plaque instability. A 2022 meta-analysis confirmed its association with major adverse cardiac events. Machine learning algorithms incorporating PFA and additional imaging features have further enhanced risk prediction beyond traditional metrics. Pericoronary fat attenuation is a promising marker for assessing coronary inflammation and could be useful in predicting plaque development, rupture, and monitoring treatment response, though further prospective studies and technical standardization are needed to fully establish its clinical benefits.","PeriodicalId":10875,"journal":{"name":"Current Atherosclerosis Reports","volume":" ","pages":"733-738"},"PeriodicalIF":5.7,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142399680","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Inhibition of the ANGPTL3/8 Complex for the Prevention and Treatment of Atherosclerotic Cardiovascular Disease. 抑制 ANGPTL3/8 复合物以预防和治疗动脉粥样硬化性心血管疾病。

IF 5.7 2区医学

Current Atherosclerosis Reports Pub Date : 2024-11-20 DOI: 10.1007/s11883-024-01254-y

Dick C Chan, Gerald F Watts

{"title":"Inhibition of the ANGPTL3/8 Complex for the Prevention and Treatment of Atherosclerotic Cardiovascular Disease.","authors":"Dick C Chan, Gerald F Watts","doi":"10.1007/s11883-024-01254-y","DOIUrl":"https://doi.org/10.1007/s11883-024-01254-y","url":null,"abstract":"Purpose of review: Dyslipidemia is a casual risk factor for atherosclerotic cardiovascular disease (ASCVD). There is an unmet need for more effective treatments for patients with dyslipidemias. Angiopoietin-like protein 3 (ANGPTL3) and ANGPTL8 play key roles in triglyceride trafficking and energy balance in humans. We review the functional role of these ANGPTL proteins in the regulation of lipoprotein metabolism, and recent clinical trials targeting ANGPTL3 and ANGPTL3/8 with monoclonal antibody and/or nucleic acid therapies, including antisense oligonucleotides and small interfering RNA.Recent findings: Cumulative evidence supports the roles of ANGPTL3 and ANGPTL8 in lipid metabolism through inhibition of lipoprotein lipase and endothelial lipase activity. ANGPTL3 and ANGPTL3/8 inhibitors are effective in lowering plasma triglycerides and low-density lipoprotein (LDL)-cholesterol, with the possible advantage of raising high-density lipoprotein (HDL)-cholesterol with the inhibition of ANGPTL3/8. Therapeutic inhibition of ANGPTL3 and ANGPTL3/8 can lower plasma triglyceride and LDL-cholesterol levels possibly by lowering production and upregulating catabolism of triglyceride-rich lipoprotein and LDL particles. However, the effect of these novel agents on HDL metabolism remains unclear. The cardiovascular benefits of ANGPTL3 and ABGPTL3/8 inhibitors may also include improvement in vascular inflammation, but this requires further investigation.","PeriodicalId":10875,"journal":{"name":"Current Atherosclerosis Reports","volume":"27 1","pages":"6"},"PeriodicalIF":5.7,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142675325","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Statin-Associated Muscle Symptoms: Identification and Recommendations for Management. 他汀类药物相关肌肉症状：识别与管理建议》。

IF 5.7 2区医学

Current Atherosclerosis Reports Pub Date : 2024-11-18 DOI: 10.1007/s11883-024-01246-y

Kevin C Maki, Carol F Kirkpatrick, Mary Katherine Cheeley, Terry A Jacobson

{"title":"Statin-Associated Muscle Symptoms: Identification and Recommendations for Management.","authors":"Kevin C Maki, Carol F Kirkpatrick, Mary Katherine Cheeley, Terry A Jacobson","doi":"10.1007/s11883-024-01246-y","DOIUrl":"10.1007/s11883-024-01246-y","url":null,"abstract":"Purpose of review: Statins are first-line pharmacotherapy for the treatment of elevated low-density lipoprotein cholesterol and are generally well-tolerated. However, some patients may experience statin-associated muscle symptoms (SAMS). This paper reviews recommendations for identification and management of patients with SAMS.Recent findings: The National Lipid Association and other professional societies have issued guidance to assist clinicians in identifying and managing patients with partial or complete statin intolerance. The most common reason for intolerance is SAMS. This review discusses strategies to achieve therapeutic objectives for atherogenic lipoprotein management in patients with SAMS. Many patients who experience SAMS can tolerate some degree of statin therapy and non-statin medications are available as adjunctive or alternative treatments. With a thorough clinician-patient discussion and shared decision-making, a treatment plan can be identified to achieve therapeutic objectives and reduce the risk of atherosclerotic cardiovascular disease.","PeriodicalId":10875,"journal":{"name":"Current Atherosclerosis Reports","volume":"27 1","pages":"5"},"PeriodicalIF":5.7,"publicationDate":"2024-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142647426","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Erosion of the Atheroma: Wicked T Cells at the Culprit Site. 动脉粥样斑块的侵蚀：罪魁祸首的邪恶 T 细胞

IF 5.7 2区医学

Current Atherosclerosis Reports Pub Date : 2024-11-16 DOI: 10.1007/s11883-024-01247-x

Shiying Lin, Yinda Yu, Leif Å Söderström, Anton Gisterå

引用次数: 0

The Emerging Potential of Apolipoprotein C-III Inhibition for ASCVD Prevention: A State-of-the-Art Review. 载脂蛋白 C-III 抑制剂在预防 ASCVD 方面的新潜力：最新研究综述

IF 5.7 2区医学

Current Atherosclerosis Reports Pub Date : 2024-11-14 DOI: 10.1007/s11883-024-01258-8

Samuel D Maidman, Robert A Hegele, Robert S Rosenson

{"title":"The Emerging Potential of Apolipoprotein C-III Inhibition for ASCVD Prevention: A State-of-the-Art Review.","authors":"Samuel D Maidman, Robert A Hegele, Robert S Rosenson","doi":"10.1007/s11883-024-01258-8","DOIUrl":"10.1007/s11883-024-01258-8","url":null,"abstract":"Purpose of review: Multiple agents are being developed that inhibit apolipoprotein (apo) C-III. This state-of-the-art review examines their potential for atherosclerotic cardiovascular disease (ASCVD) risk reduction.Recent findings: Apo C-III, an apolipoprotein on the surface of triglyceride-rich lipoproteins (TRLs), impairs clearance of TRLs through both lipoprotein lipase dependent and independent pathways, thereby resulting in increased concentrations of triglycerides. Apo C-III has also been shown to have pro-atherogenic effects when bound to high-density lipoprotein (HDL) particles. Classical and genetic epidemiology studies provide support for the concept that apo C-III is associated with an increased risk of ASCVD events. Drug efficacy of agents that silence APOC3 mRNA has been studied in populations with varying hypertriglyceridemia severity, including those with familial chylomicronemia syndrome, multifactorial chylomicronemia syndrome/severe hypertriglyceridemia, and mixed hyperlipidemia. Randomized controlled trials have reported significant reductions in TG and non-HDL cholesterol levels among these patients treated with APOC3 inhibitors. Upcoming clinical outcomes trials seek to establish a role for APOC3 inhibitors to reduce risk of ASCVD.","PeriodicalId":10875,"journal":{"name":"Current Atherosclerosis Reports","volume":"27 1","pages":"3"},"PeriodicalIF":5.7,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142616383","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0